Business Context and Reporting Period
Company: iRhythm Technologies, Inc. (IRTC)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Quarter and six months ended June 30, 2025
Business Overview: iRhythm is a digital healthcare company providing ambulatory cardiac monitoring services via its Zio System, a wearable biosensor and cloud-based analytics platform. The company operates as a single reportable segment focused on global ambulatory cardiac monitoring.
Key Financial Metrics
| Metric (in thousands) | Q2 2025 | Q2 2024 | YTD 2025 | YTD 2024 |
|---|---|---|---|---|
| Net Revenue | $186,687 | $148,047 | $345,364 | $279,976 |
| Gross Profit | $132,857 | $103,471 | $242,073 | $190,987 |
| Gross Margin | 71.2% | 69.9% | 70.1% | 68.2% |
| Net Loss | $(14,218) | $(20,107) | $(44,918) | $(65,774) |
| Adjusted EBITDA | $15,696 | $4,991 | $13,061 | $(7,130) |
| Cash & Equivalents | $309,105 | $419,597 | $309,105 | $419,597 |
| Marketable Securities | $236,435 | $115,956 | $236,435 | $115,956 |
| Total Debt (Convertible Notes) | $648,007 | $646,443 | $648,007 | $646,443 |
Note: Debt figures represent the carrying amount of 1.50% Senior Convertible Notes due 2029. Principal amount is $661.25 million.
Material Changes vs. Prior Period
- Revenue Growth: Net revenue increased 26% year-over-year (YoY) in Q2 2025 and 23% YoY for the six-month period, driven primarily by increased volume of iRhythm Services, particularly the Zio AT product line.
- Profitability Improvement: Net loss narrowed by 29% in Q2 and 32% YTD compared to 2024. Adjusted EBITDA turned positive ($15.7M in Q2) compared to $5.0M in Q2 2024.
- Operating Expenses: Selling, General, and Administrative (SG&A) expenses increased 18% in Q2 and 14% YTD, largely due to higher headcount costs, legal fees, and provisions for credit losses. Research and Development (R&D) expenses increased 7% in Q2 and 16% YTD.
- Impairment Charges: The company recorded a $2.5 million impairment charge in Q2 2025 related to capitalized internal-use software for the Zio Watch, which will not be commercially launched. No such charge was recorded in the prior year.
- Acquired IPR&D: Expenses of $1.7 million (Q2) and $2.0 million (YTD) were recognized related to the Technology License Agreement with BioIntelliSense, Inc. (BioIS).
- Liquidity: Cash and cash equivalents decreased from $419.6M to $309.1M, while marketable securities increased significantly from $116.0M to $236.4M, reflecting investment activity.
Guidance, Outlook, and Risks
- Outlook: Management expects to continue investing in business growth, which may require additional equity or debt financing. The company believes current liquidity is sufficient for the next 12 months.
- Strategic Developments:
- BioIS Agreement: BioIS achieved the first of two regulatory milestones in June 2025. The company is in the process of canceling $10.0 million in Milestone Notes plus accrued interest.
- Verily Collaboration: The company is actively engaged with Verily to formally terminate the Development Collaboration Agreement regarding the Zio Watch.
- Key Risks & Contingencies:
- Legal Proceedings: A securities class action lawsuit remains in discovery (individual defendants dismissed except CEO). Two patent infringement lawsuits are ongoing against Welch Allyn and Bardy Diagnostics (subsidiaries of Baxter International). The company is also defending against a DOJ subpoena regarding document production, with an appeal currently stayed.
- Regulatory: The company is addressing FDA Form 483 observations from July 2024 inspections regarding complaint handling and medical device reporting. Failure to resolve these could lead to enforcement actions.
- Reimbursement: Revenue is heavily dependent on third-party payors (52% contracted commercial, 24% Medicare). Changes in CMS reimbursement rates or payer contracts pose significant risk.
- Supply Chain: Reliance on single-source vendors for critical components (adhesives, housings) creates supply risk.
Investor Verification Checklist
- Revenue Quality: Verify the sustainability of the 26% revenue growth and the impact of higher contractual allowance reserves on future margins.
- Legal Exposure: Monitor the status of the DOJ appeal regarding document production and the outcomes of the patent litigation with Baxter subsidiaries.
- Regulatory Compliance: Track the resolution of FDA Form 483 observations and any potential impact on operations or product distribution.
- Debt Structure: Review the terms of the $661.3 million Senior Convertible Notes due 2029, including conversion triggers and potential dilution.
- Strategic Investments: Assess the progress of the BioIS regulatory milestones and the financial impact of the $10 million note cancellation.
- Impairment Trends: Evaluate if the $2.5 million software impairment is an isolated event or indicative of broader R&D inefficiencies.